IL-12 Cytokine for Hematopoietic Stem Cell Engraftment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hematopoietic stem cell transplantation (HSCT) is a high-risk procedure with significant complications such as infection, graft-versus-host disease, and development of new malignancies, necessitating the need for novel agents that enhance hematopoietic recovery while reducing these risks.
Innovation Solution
Administration of recombinant human interleukin-12 (rHuIL-12) or its mouse homologue, IL-12, to stimulate hematopoiesis and reconstitute bone marrow, either before or after total body irradiation, through interaction with IL-12 receptors on hematopoietic stem cells and niche cells, thereby enhancing engraftment and recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hematopoietic stem cell transplantation is performed to treat life-threatening diseases, then patients can receive potentially curative therapy, but the risk of fatal complications such as infection and graft-versus-host disease increases significantly
Solution Approach 1:
The patent applies preliminary action by administering IL-12 before hematopoietic stem cell transplantation to pre-condition the bone marrow niche and enhance stem cell engraftment. This preparatory treatment modifies the recipient's bone marrow environment in advance to promote successful transplantation and reduce complications, thereby improving transplant reliability while managing infection risks.
2Reliability
If high dose therapy is administered to eradicate tumor cells, then cancer remission is achieved, but hematopoietic damage and recovery time increase
Solution Approach 1:
The patent uses IL-12 as an intermediary substance that mediates between the damaging effects of high-dose therapy and the need for rapid hematopoietic recovery. IL-12 stimulates hematopoietic stem cells and enhances bone marrow function, acting as a bridge that accelerates recovery without compromising the efficacy of cancer treatment, thus reducing the time loss associated with hematopoietic suppression.
3Reliability
If allogeneic stem cells are transplanted to provide a new immune system, then graft versus tumor effect is enhanced, but graft-versus-host disease risk increases
Solution Approach 1:
The patent applies parameter changes by modifying the bone marrow niche environment through IL-12 administration, which alters the physiological parameters of the recipient's bone marrow. This creates a more favorable environment for allogeneic stem cell engraftment and reduces the immunological mismatch that leads to graft-versus-host disease, while preserving the graft versus tumor effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
rHuIL-12 effectively promotes hematopoietic recovery and survival in irradiated subjects, comparable to bone marrow cell transplants, by increasing IL-12Rβ2-expressing cells, including megakaryocytes and osteoblasts, leading to robust blood cell recovery and reduced mortality.
Implementation Method 1
through interaction with IL-12 receptors on hematopoietic stem cells and niche cells, thereby enhancing engraftment and recovery
Data Source
AI summary
Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for improving hematopoietic recovery HSCT transplantation in a subject. In particular, the instant disclosure provide exemplary methods and compositions comprising IL-12 promoted hematopoiesis and increased the recovery of peripheral blood cells and survival in lethally irradiated mice as effectively as a BMCT, indicating that rHuIL-12 therapy can to increase HSC engraftment following HSCT. We identified IL-12Rβ2 expressing cells in irradiated mouse bone marrow which are potential targets of IL-12. Administration of rMuIL-12 increased the number of IL-12R□2 expressing Lin− cells in mouse bone marrow, indicating that bone marrow HSCs and niche cells are the direct target of rMuIL-12 and that hematopoiesis-promoting activity of rMuIL-12 is mediated by IL-12 receptors on HSCs. Finally, we show expression of IL-12β2 on human bone marrow lin− and CD34+ cells, indicating a potential role for IL-12 in human transplantation.